# Radiation and Combination Immunotherapy for Melanoma

> **NCT03850691** · PHASE2 · COMPLETED · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 4 (actual)

## Conditions studied

- Metastatic Melanoma

## Interventions

- **DRUG:** Aldesleukin: All Patients
- **DRUG:** Nivolumab: Cohort 1 (Cutaneous)
- **DRUG:** Nivolumab: Cohort 2 (Ocular)
- **DRUG:** Ipilimumab: Cohort 2 (Ocular)

## Key facts

- **NCT ID:** NCT03850691
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-28
- **Primary completion:** 2021-05-04
- **Final completion:** 2022-12-12
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2024-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03850691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03850691, "Radiation and Combination Immunotherapy for Melanoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03850691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*